|
| |
IomaiIomai Corporation discovers and develops vaccines and immune system stimulants, delivered via a novel, needle-free technology called transcutaneous immunization (TCI). TCI taps into the unique benefits of a major group of antigen-presenting cells found in the outer layers of the skin to generate an enhanced immune response.
Iomai is leveraging TCI to enhance the efficacy of existing vaccines, enable new vaccines that are viable only through transcutaneous administration and expand the global vaccine market. We currently have four product candidates in development: three targeting influenza and pandemic flu and one to prevent E. coli-related travelers’ diarrhea.
| Contact Details: |
| 20 Firstfield Road |
| Gaithersburg |
| MD |
| 20878 |
| United States of America |
| Tel: | 301-556-4500 |
| Fax: | 301-556-4501 |
| Email: | |
| WWW: | www.iomai.com/
|
|
Loading...
|
Recent Publications by Iomai: |  |
Controlled, single-step, stratum corneum disruption as a pretreatment for immunization via a patch.
A Skin Prep System (SPS) has been developed to provide a well-tolerated... | 18th July, 2008
| Iomai Corporation, 20 Firstfield Road, Suite 250, Gaithersburg, MD 20878,
| Vaccine. 2008 May 23;26(22):2782-7. Epub 2008 Mar 28.
DOI Direct Link |
Use of a patch containing heat-labile toxin from Escherichia coli against travellers' diarrhoea: a phase II, randomised, double-blind, placebo-controlled field trial.
BACKGROUND: Enterotoxigenic Escherichia coli (ETEC) is a major cause of... | 27th June, 2008
| IOMAI Corporation, Gaithersburg, MD, USA.
| Lancet. 2008 Jun 14;371(9629):2019-25.
DOI Direct Link |
Transcutaneous immunization with heat-labile enterotoxin: development of a needle-free vaccine patch.
The skin is an attractive target for vaccine delivery. Adjuvants and... | 6th December, 2007
| Iomai Corporation, 20 Firstfield Road, Suite 250, Gaithersburg, MD 20878,
| Expert Rev Vaccines. 2007 Oct;6(5):809-19.
DOI Direct Link |
Safety and immunogenicity of an enterotoxigenic Escherichia coli vaccine patch containing heat-labile toxin: use of skin pretreatment to disrupt the stratum corneum.
Transcutaneous immunization allows safe delivery of native heat-labile... | 15th June, 2007
| IOMAI Corporation, 20 Firstfield Road, Gaithersburg, MD 20878, USA.
| Infect Immun. 2007 May;75(5):2163-70. Epub 2007 Jan 29.
DOI Direct Link |
Mass vaccination: solutions in the skin.
The skin is populated with Langerhans cells, thought to be efficient,... | 26th January, 2007
| Iomai Corporation,
| Curr Top Microbiol Immunol. 2006;304:247-68.
|
→View more Iomai research publications. |
 Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.
This page has been viewed 171 times since April 2007, the link to the organisation's website has been followed 36 times Recent Search Terms used to find this page: site:www.bioportfolio.com iomai.com,vaccine | iomai ehec | iomai.com | . Search for more companies in Gaithersburg Search for more companies in MD This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.BioPortfolio search results for Iomai |
